Organo-Specific Nano Peptides and Mitochondrial Modulators for Therapeutic Rejuvenation and Disease Modification: A Translational Perspective

Abstract

Cellular senescence and mitochondrial dysfunction are hallmark features of aging and contribute to the pathogenesis of numerous age-related diseases, including neurodegeneration, cardiovascular disorders, and metabolic syndrome. Senescent cells exhibit irreversible growth arrest accompanied by a pro-inflammatory secretory phenotype, while impaired mitochondrial function exacerbates oxidative stress and energy deficits, collectively driving tissue decline and systemic dysfunction. Therapeutic strategies targeting these interconnected pathways offer promising avenues for mitigating age-associated morbidity.
Nano Peptides and Mito Organelles (MO) therapies represent innovative biologic modalities designed to restore cellular homeostasis by directly modulating mitochondrial function and reducing senescent cell burden. Nano Peptides are engineered short amino acid sequences encapsulated within nanoparticle delivery systems that facilitate targeted tissue penetration and cellular uptake. MO peptides specifically localize to mitochondria to enhance bioenergetics, promote mitophagy, and reduce reactive oxygen species production. Together, these approaches aim to rejuvenate cellular metabolism and attenuate the detrimental effects of senescence. Preclinical studies in aged animal models have demonstrated that administration of Nano Peptides and MO therapies improves mitochondrial respiration, decreases markers of senescence, and enhances tissue regeneration and functional outcomes. Early-phase clinical trials indicate favorable safety profiles and suggest potential efficacy in conditions such as frailty, sarcopenia, and mild cognitive impairment. Biomarker analyses reveal improvements in mitochondrial biomarkers and reduced systemic inflammation. The integration of Nano Peptides and MO therapies holds significant promise for transforming treatment paradigms in aging-related diseases. Future directions include refining peptide design for enhanced targeting and stability, combining these therapies with senolytics or metabolic modulators, and conducting larger randomized controlled trials to validate clinical benefits. Ultimately, these biologics could offer precision interventions that restore cellular vitality and delay or reverse age-related functional decline.

Keywords:Aging, Nano peptides, Cell Senescence, Mitochondrial Disfunction

Introduction

Aging is characterized by a progressive and multifactorial decline in physiological resilience, functional capacity, and metabolic homeostasis across nearly all organ systems. As individuals age, there is a cumulative deterioration in the structure and function of cells, tissues, and organs, leading to increased vulnerability to chronic diseases such as type 2 diabetes, neurodegenerative disorders, cardiovascular disease, and sarcopenia [1-4]. Globally, the population over the age of 60 is expected to double by 2050, reaching over 2 billion people [5]. As such, the aging population is estimated to exert profound pressure on healthcare systems and underscoring the need for effective interventions that promote healthy aging rather than merely managing late-stage disease [6].

At the cellular level, the aging process is driven by a constellation of interrelated hallmarks, prominently including mitochondrial dysfunction and the accumulation of reactive oxygen species (ROS) [7,8]. Mitochondria are not only bioenergetic powerhouses but also crucial signaling hubs that regulate cell fate decisions, immune activation, and metabolic flexibility [9]. With advancing age, mitochondrial DNA (mtDNA) mutations accumulate, oxidative phosphorylation efficiency declines, and ROS production increases, leading to damage of cellular macromolecules and disruption of redox signaling [10]. Age-related mitochondrial damage is further exacerbated by impaired mitophagy and biogenesis, resulting in a feed-forward loop of oxidative stress, senescence, and cellular dysfunction [11].

Recent evidence suggests that mitochondrial dysfunction is a key mechanistic driver not only of aging itself but also of a range of age-related pathologies. For example, alterations in mitochondrial dynamics and redox homeostasis have been directly implicated in the pathogenesis of Alzheimer’s disease, insulin resistance, and atherosclerosis. Adverse changes in mitochondrial dynamics have been well established in the pathophysiology linking insulin resistance, diabetes, and cardiovascular diseases [12,13]. Accumulating reviews of molecular mechanisms demonstrate the potential by which insulin-signaling dysregulation and insulin resistance contribute to the pathogenesis and progression of Alzheimer’s Disease, deepening the analysis of complex mechanisms involved in ROS production under oxidative stress and the intersection of AD and type 2 diabetes (T2D) [14-16]. Elevated ROS, once considered merely toxic byproducts, are now recognized as pivotal mediators of inflammatory signaling and epigenetic dysregulation, linking mitochondrial stress to systemic aging phenotypes [17,18]. These insights have galvanized growing interest in therapeutic strategies that target the mitochondrial axis of aging, including the use of mitochondria-targeted antioxidants, mitochondrial biogenesis enhancers, and increasingly, peptide-based therapies that modulate organ-specific cellular signaling. As the field of geroscience advances, there is increasing consensus that targeting mitochondrial dysfunction offers a promising route to simultaneously address multiple chronic diseases and improve healthspan. This shift from disease-specific interventions to multi-targeted regenerative strategies reflects a new paradigm in biomedicine. The emerging con ceptualization seeks to reestablish physiological homeostasis at the organellar and cellular level rather than managing the downstream consequences of dysfunction.

In this context, organ-specific nano peptides (NP) and mitochondrial modulators (i.e., mito organelles [MO]) represent a novel frontier in anti-aging therapeutics [19]. By engaging mitochondrial and metabolic pathways with high tissue specificity, these biologics aim to restore the bioenergetic and signaling functions that decline with age, potentially offering disease-modifying effects across multiple organ systems.

Mitochondrial Dysfunction and Organelle-Specific Therapies

The central role in the regulation of cellular energy metabolism, redox balance, apoptosis, and innate immune signaling, and their progressive dysfunction represents the key target for therapeutic advances to prevent or delay age-associated diseases. The physiological levels of ROS exist as important signaling roles, regulating gene expression, proliferation, and immune function; however, in aging and age-related disease the ROS production exceeds homeostatic balance mechanisms which in turn disrupts cellular redox homeostasis [20,21]. The chronicity leads to oxidative damage of mitochondrial DNA (mtDNA), proteins, and lipids [10,13,22]. ROS-induced damage creates a vicious cycle of mitochondrial injury, functional decline, and further ROS production that not only impairs energy production but also activates pro-senescent and pro-inflammatory pathways such as p53, NF-κB, and the NLRP3 inflammasome [23,24].

Mitochondrial dysfunction also contributes directly to cellular senescence, a stable cell-cycle arrest state characterized by the secretion of inflammatory mediators, extracellular matrix-modifying enzymes, and growth factors, collectively termed the senescence- associated secretory phenotype (SASP) [25]. Emerging evidence indicates that mitochondrial dysfunction-associated senescence (MiDAS) is a distinct senescent phenotype driven by chronic energy stress and altered NAD+/NADH and AMP/ATP ratios, leading to AMPK activation and transcriptional reprogramming via PGC-1α, ATF4, and p21 [26]. Given the centrality of mitochondrial dysfunction in aging, there is increasing interest in therapeutic interventions that restore or enhance mitochondrial function. Among these, organelle-specific and organ-targeted peptide therapies have emerged as a novel and potentially transformative strategy. Organo-specific peptides, short amino acid sequences derived from tissue-specific proteins, can engage endogenous regenerative pathways, modulate inter-organ communication, and enhance mitochondrial resilience [27,28]. These peptides may act directly on mitochondria by stabilizing mitochondrial membranes, enhancing mitophagy, or modulating key signaling axes such as the ROS-PGC-1α-NRF1/2 pathway [29].

In particular, European Wellness (EW) has developed formulations to target specific tissues (e.g., liver, pancreas, brain, gonads) and deliver bioactive signals that may support mitochondrial biogenesis, restore ATP production, and mitigate ROS-induced damage. Preclinical evidence suggests that certain peptides can upregulate SIRT3, TFAM, and OPA1, key regulators of mitochondrial homeostasis and reduce oxidative burden by promoting antioxidant [30]. Moreover, the ability of peptide-based therapies to selectively target dysfunctional organ systems represents a distinct advantage over systemic small-molecule drugs. Unlike broad-acting antioxidants, which can disrupt physiological redox signaling, peptide- based therapies can provide a precision biological signal that is both tissue-specific and functionally adaptive, potentially leading to restoration of homeostasis without systemic off-target effects [31,32].

Therapeutic Rationale and Mechanistic Framework Conceptual Framework

Aging-related organ decline reflects not only cumulative cellular injury but also the erosion of the molecular communication networks that coordinate repair, regeneration, and systemic homeostasis. Effective rejuvenation strategies must therefore address these signaling deficits directly, restoring the cues that maintain organ vitality rather than simply alleviating symptoms.

Organo-specific peptide therapy offers a biologically integrated approach to counter age-associated functional loss. Short-chain peptides derived from tissue-specific proteomes can recapitulate endogenous regulatory signals involved in organ maintenance, metabolic adaptation, and immune modulation. Their high specificity and low toxicity distinguish them from conventional small molecules or generalized biologics, which often lack targeted engagement with the intended tissue or cellular compartment. Therapeutic platforms use nanocarrier systems to shield peptides from enzymatic degradation, facilitate cellular uptake, and enhance biodistribution to specific tissues [33]. The formulations designed by EW [34], for example, can adapt their activity to the biochemical environment of the target organ, providing context-sensitive restoration of function. Early evidence indicates that EW peptide preparations can promote mitochondrial biogenesis, improve ATP generation efficiency, and recalibrate stress-responsive pathways. By combining horizontal specificity (targeting the organ of origin) with vertical specificity (acting at the mitochondrial level), this dual- axis approach addresses both systemic and intracellular drivers of decline. Compared with stem cell therapies, systemic hormones, or broad-spectrum antioxidants, which often face limitations in targeting and safety, these peptide-based platforms are engineered for precision biocompatibility, controlled pharmacodynamics, and minimal immunogenicity, making them well suited for translation across aging and disease settings.

Mechanism of Action

The therapeutic impact of organo-specific peptide platforms derives from their ability to engage precise molecular targets through coordinated uptake, compartmentalized signaling, and bidirectional communication between mitochondria and the nucleus. Acting at both the tissue and subcellular levels, these mechanisms enable restoration of function in organs affected by age- or disease-related decline. Following parenteral administration, peptides enter systemic circulation and selectively accumulate in their tissue of origin through receptor-mediated recognition and microenvironmental affinity for specific cell types [35]. Nanoformulation enhances stability and delivery efficiency by shielding peptides from enzymatic degradation and enabling efficient passage across cellular barriers [36]. Within target cells, peptides can localize to defined subcellular domains, including mitochondria, where specialized targeting sequences facilitate entry into the organelle. Once inside, they may influence mitochondrial regulatory proteins, transcriptional coactivators, or metabolic enzymes, thereby modulating energy production, redox balance, and adaptive stress responses [13,22,36]. This layered targeting strategy provides a mechanistic basis for their therapeutic specificity and functional efficacy.

Mitochondrial Retrograde Signaling and Nuclear Crosstalk

Peptide-driven enhancement of mitochondrial function activates a retrograde signaling cascade in which restored mitochondrial dynamics and balanced redox status influence nuclear gene expression. Metabolic intermediates and second messengers (i.e., ROS, NAD+/NADH, ATP/AMP ratios, and calcium flux) serve as conduits for this cross-compartment communication, engaging transcriptional regulators including PGC-1α, NRF1/2, and TFAM that govern mitochondrial biogenesis and metabolic equilibrium [29]. In the therapeutic setting, this retrograde signaling represents not a mere stress adaptation but a directed recalibration of cellular energy and repair programs. Through promoting mitochondrial fusion, supporting selective mitophagy, and optimizing electron transport chain efficiency, peptides foster a shift from a catabolic, pro-senescent state toward one that favors anabolic processes, regenerative capacity, and sustained redox homeostasis [9,13].

Modulation of Key Pathways: ROS, AMPK, and PGC-1α

Organo-specific peptides modulate key transcriptional and enzymatic regulators that integrate cellular metabolism with mitochondrial health. Instead of indiscriminately quenching ROS, a strategy that can disrupt physiological signaling, these peptides recalibrate redox tone by enhancing endogenous antioxidant defenses, including superoxide dismutase 2 (SOD2), catalase, and glutathione peroxidase. This restores a functional balance between ROS-mediated signaling and oxidative damage [37]. Improved ATP generation reduces maladaptive, chronic AMPK activation while preserving its transient, adaptive activity, thereby supporting autophagy, glucose utilization, and fatty acid oxidation [38]. Upregulation of PGC-1α, a central driver of mitochondrial biogenesis, emerges through convergent ROS- and AMPK-dependent pathways. Peptides may further potentiate this response by activating upstream regulators such as SIRT1 and CREB, leading to transcription of nuclear-encoded mitochondrial genes [39]. Through the integration of redox optimization, metabolic recalibration, and biogenic signaling, organo-specific peptides re-establish energy balance, dampen chronic inflammatory tone, and enhance resilience to cellular stress, core hallmarks of functional rejuvenation.

Composition and Targeting Specificity

Organo-specific peptide therapies are based on the principle that short-chain peptides, derived from the proteomes of specialized tissues, retain biological signatures reflective of their source organ’s physiological role. These peptides can be isolated, synthesized, or recombinantly expressed, and are formulated into combinations tailored to the tissue or organ system most affected by age-related decline. Formulations often integrate empirically selected peptides from multiple tissues to address both systemic aging mechanisms and localized organ dysfunction. Examples include liver-derived peptides for metabolic regulation, detoxification, and glucose-lipid homeostasis; pancreatic peptides for insulinotropic activity and glycemic control; placental peptides for endocrine resilience, immunomodulation, and regenerative signaling; gastric and intestinal peptides for mucosal integrity, nutrient sensing, and microbiota-host communication; mesenchymal peptides for stromal support and extracellular matrix remodeling; and kidney or endothelial peptides for filtration, vascular tone, and fluid balance. By combining peptides from diverse origins, these therapies aim to restore the multi-axis inter-organ signaling networks that become fragmented in aging and chronic disease.

Bench to Bedside Applications

Preclinical investigations and early translational efforts demonstrate broad therapeutic potential across multiple age-associated pathologies. The systemic integration of these peptides makes them uniquely suited for intervention in complex chronic diseases characterized by cellular senescence, energy imbalance, and hormonal insufficiency.

Metabolic Syndrome and Endocrine Disorders

Peptide formulations have been documented as efficacious in preclinical models of metabolic syndrome [40]. The findings address core features including obesity, insulin resistance, hepatic steatosis, and dyslipidemia. Metabolic and endocrine targeting peptides act at multiple nodes within the metabolic axis liver, pancreas, gastrointestinal tract, and kidney enabling a system-level correction of disrupted glucose-lipid homeostasis. Studies demonstrate peptide-mediated upregulation of AMPK, normalization of adipokine profiles, attenuation of hepatic lipid accumulation, and improved insulin sensitivity [41]. By engaging organ-specific mitochondrial pathways, these therapies enhance bioenergetic capacity and reduce chronic low-grade inflammation, both critical contributors to endocrine and metabolic decline with age. Organo-specific peptides also represent innovative approaches to overcoming challenges in obesity treatment, offering precision, efficacy, and the potential to address obesity’s underlying metabolic dysfunctions. Ongoing research and development in these areas holds promise for advancing therapeutic strategies against obesity and its associated complications.

Gastrointestinal (GI) Injury

The GI tract is a highly dynamic organ system characterized by rapid cellular turnover and intrinsic regenerative capacity. However, aging along with chronic or severe insults, such as those arising from inflammatory bowel disease or ischemic injury can exceed the tissue’s innate repair mechanisms, leading to persistent mucosal damage and impaired function. In this context, peptide-based therapeutics have emerged as a promising class of regenerative agents that harness the specificity and bioactivity of short amino acid sequences to modulate critical pathways involved in tissue repair. These peptides exert multifaceted effects, including stimulation of epithelial cell proliferation, maintenance of mucosal barrier integrity, regulation of inflammatory responses, promotion of angiogenesis, and inhibition of apoptosis. Collectively, these actions facilitate an optimized microenvironment conducive to coordinated mucosal healing. Furthermore, certain peptide candidates demonstrate the ability to modulate the gut microbiome and enhance host-microbial crosstalk, factors increasingly recognized as integral to intestinal homeostasis and regeneration to restore the dysregulated gutbrain axis apparent in aging.

Neurodegeneration and Cognitive Aging

Neuroendocrine peptide formulations, incorporating hypothalamic, pituitary, and CNS-derived peptides, are under investigation for their role in mitigating age-related cognitive decline and neurodegeneration. These peptides exert regulatory control over neuroinflammatory pathways, blood-brain barrier integrity, and neuronal mitochondrial function. In vitro and in vivo studies have reported enhanced neural stem cell viability, increased ATP production in cortical neurons, and reductions in pro-inflammatory cytokine expression (e.g., IL-1β, TNF-α). Potential clinical applications include early-stage AD, mild cognitive impairment, and stress-related cognitive dysfunction, particularly where neuroendocrine disruption (e.g., HPA axis dysregulation) intersects with mitochondrial decline [1,15,27]. Organo-specific peptide interventions may thus represent a novel class of neuroregenerative agents, operating at the intersection of immunometabolism and mitochondrial neurobiology.

Sex-Specific Revitalization

Hormonal modulation has been also shown to be increased as evidenced by circulating levels of free testosterone, estradiol, luteinizing hormone (LH), and follicle-stimulating hormone (FSH), consistent with reactivation of hypothalamic-pituitary-gonadal axis (HPG) signaling. These target HPG axis function by enhancing gonadotropin signaling, sex hormone synthesis, and gametogenesis. Preclinical findings indicate they may increase LH/FSH receptor sensitivity, stimulate steroidogenic enzyme activity, and boost ATP production within Leydig and granulosa cells, supporting fertility potential alongside hormonal balance [42]. By combining tissue-derived peptides that influence both mitochondrial metabolism and hormonal regulation, these therapies target a critical axis of functional aging where energy balance and endocrine integrity intersect. Male-focused blends incorporate peptides that enhance mitochondrial ATP production, stimulate testosterone biosynthesis, reduce inflammatory tone, and support neuromuscular function through coordinated action on peripheral tissues and central neuroendocrine pathways. Female-focused blends may be designed to promote estradiol and progesterone synthesis, stabilize reproductive cycles, and improve mitochondrial performance in oocytes and endometrial cells. Placental peptides contribute additional immunotolerant and anti-apoptotic effects, particularly valuable in peri- and post-menopausal contexts. Through organotropic delivery and optimized intracellular uptake, these formulations address energy imbalance, oxidative stress, and endocrine insufficiency in parallel. By restoring HPG feedback sensitivity, they may improve gonadotropin signaling, steroidogenesis, and gametogenesis, supporting both fertility and sexual health. As potential adjuncts or alternatives to conventional hormone replacement therapies, they offer the prospect of targeted benefits with a reduced risk of oncogenic or thrombotic complications.

Evidence of Efficacy

Emerging real-world evidence supports the biological activity of organ-specific peptide formulations in human subjects. Quantitative serum analyses have demonstrated significant increases in key endogenous peptides post-administration, including mitochondrial bioactive peptides (e.g. Humanin) [43]. In observational datasets, serum Humanin concentrations rose from sub-physiological baseline levels (~0.15 μg/mL) to peak levels exceeding 0.75 μg/mL within 48 hours of peptide administration, with sustained elevations lasting up to seven days post-dose in some individuals [44]. These pharmacodynamic profiles suggest not only systemic bioavailability but also a capacity for endocrine and mitochondrial signaling engagement.

Functional Outcomes

Beyond pharmacokinetic characterization, observational cohorts treated with tailored organo-specific peptide protocols have demonstrated meaningful improvements in both biochemical and functional endpoints. Peripheral blood mononuclear cells (PBMCs) from treated participants exhibited enhanced ATP synthesis and reduced ROS production, indicating improved mitochondrial efficiency [45]. Clinically, these molecular changes correlated with self-reported gains in vitality, libido, sleep quality, and physical stamina, supported by objective increases in physical activity scores and reductions in fatigue indices across serial assessments. Collectively, these findings suggest that short-chain peptide combinations function not only as signaling modulators but also as enhancers of mitochondrial bioenergetics and endocrine homeostasis. The safety profile of these peptide formulations has been favorable, with adverse events limited primarily to transient local injection site reactions and no serious systemic effects reported in over 500 treatment cycles. Identified contraindications remain conservative, including active or recent malignancy, peptide hypersensitivity, and immunological disorders [46]. Treatment protocols typically employ cyclical regenerative regimens delivered via intramuscular or subcutaneous injections in 3-4 session courses, repeated 2-3 times annually, with dosing individualized by patient age, sex, and therapeutic goals. Such protocols have proven feasible in outpatient and wellness settings, supporting the potential for broader clinical translation pending rigorous validation.

This multi-organ targeting strategy integrates regenerative peptide signaling with mitochondrial functional enhancement, reflecting advances in geroscience and cellular bioenergetics. By incorporating peptides from metabolically active organs (e.g., liver, pancreas), reproductive tissues (e.g., ovary, testis, placenta), and the central nervous system, these therapies aim to restore complex inter-organ communication networks disrupted during aging. Observed enhancements in mitochondrial ATP production, sex hormone regulation, and functional capacity lend translational plausibility to this approach.

Nevertheless, the evidence base remains predominantly observational or preclinical, underscoring the urgent need for randomized controlled trials (RCTs) to rigorously establish dose-response relationships, confirm mechanistic pathways, and evaluate long-term efficacy and safety. Challenges such as interindividual variability, placebo effects, and limited longitudinal data currently constrain definitive conclusions. Future efforts should prioritize development of standardized peptide panels tailored to specific clinical indications, including sarcopenia, metabolic syndrome, infertility, and neurodegeneration, and explore synergistic integration with established pharmacotherapies (e.g., metformin, clomiphene, hormone replacement). Advancement in targeted delivery technologies to optimize intracellular and mitochondrial bioavailability will be critical for maximizing therapeutic impact. Complementary omics-based biomarker discovery may further enable patient stratification and individualized treatment optimization, facilitating regulatory pathway definition through peptide identity verification, stability testing, and Good Manufacturing Practice (GMP) production standards [47].

Organo-specific peptide therapies represent a promising frontier in regenerative medicine, uniquely positioned to restore mitochondrial function and endocrine balance across multiple organ systems impacted by aging. By integrating precision targeting biologically informed formulations, these approaches offer potential advantages over conventional treatments in efficacy and safety. Realizing this promise will require rigorous clinical validation, standardized manufacturing, and biomarker-driven patient stratification to ensure optimized, personalized interventions. Together, these efforts lay a clear path toward translating peptide-based mitochondrial and endocrine modulation into broadly applicable, transformative therapies for age-related functional decline.

References

1. Tenchov R, Sasso JM, Wang X and Zhou QA (2024) Aging Hallmarks and Progression and Age-Related Diseases: A Landscape View of Research Advancement. ACS Chem Neurosci 15(1): 1-30.
2. Li Z, Zhang Z, Ren Y, Wang Y, Fang J, et al (2021) Aging and age-related diseases: from mechanisms to therapeutic strategies. Biogerontology 22(2): 165-187.
3. Guo J, Huang X, Dou L, Yan M, Shen T, et al (2022) Aging and aging-related diseases: from molecular mechanisms to interventions and treatments. Signal Transduct Target Ther 7(1): 391.
4. Tenchov R, Sasso JM, Wang X and Zhou QA (2024) Aging Hallmarks and Progression and Age-Related Diseases: A Landscape View of Research Advancement. ACS Chem Neurosci 15(1): 1-30.
5. Noto S (2023) Perspectives on Aging and Quality of Life. Healthc Basel Switz 11(15): 2131.
6. Gianfredi V, Nucci D, Pennisi F, Maggi S, Veronese N, et al (2025) Aging, longevity, and healthy aging: the public health approach. Aging Clin Exp Res 37(1): 125.
7. Maldonado E, Morales-Pison S, Urbina F and Solari A (2023) Aging Hallmarks and the Role of Oxidative Stress. Antioxid Basel Switz 12(3): 651.
8. Somasundaram I, Jain SM, Blot-Chabaud M, Pathak S, Banerjee A, et al (2024) Mitochondrial dysfunction and its association with age-related disorders. Front Physiol 15: 1384966.
9. Trinchese G, Cimmino F, Catapano A, Cavaliere G and Mollica MP (2024) Mitochondria: the gatekeepers between metabolism and immunity. Front Immunol 15: 1334006.
10. Srivastava S (2017) The Mitochondrial Basis of Aging and Age-Related Disorders. Genes 8(12): 398.
11. Miwa S, Kashyap S, Chini E and von Zglinicki T (2022) Mitochondrial dysfunction in cell senescence and aging. J Clin Invest 132(13): e158447.
12. García-Peña LM, Abel ED and Pereira RO (2024) Mitochondrial Dynamics, Diabetes, and Cardiovascular Disease. Diabetes 73(2): 151-161.
13. Chen W, Zhao H and Li Y (2023) Mitochondrial dynamics in health and disease: mechanisms and potential targets. Signal Transduct Target Ther 8(1): 333.
14. Potenza MA, Sgarra L, Desantis V, Nacci C and Montagnani M (2021) Diabetes and Alzheimer’s Disease: Might Mitochondrial Dysfunction Help Deciphering the Common Path? Antioxid Basel Switz 10(8): 1257.
15. Rodriguez-Casado A, Alvarez MI, Merino JJ, Toledano-Díaz A and Toledano A (2025) Relationship between Alzheimer’s Disease and Type 2 Diabetes: Critical Review On Cellular and Molecular Common Pathogenic Mechanisms. Curr Alzheimer Res 22(2): 92-122.
16. Alzarea EA, Al-Kuraishy HM, Al-Gareeb AI, Alexiou A, Papadakis M, et al (2025) The Conceivable Role of Metabolic Syndrome in the Pathogenesis of Alzheimer’s Disease: Cellular and Subcellular Alterations in Underpinning a Tale of Two. Neuromolecular Med 27(1): 35.
17. Jomova K, Raptova R, Alomar SY, Alwasel SH, Nepovimova E, et al (2023) Reactive oxygen species, toxicity, oxidative stress, and antioxidants: chronic diseases and aging. Arch Toxicol 97(10): 2499-2574.
18. Afzal S, Abdul Manap AS, Attiq A, Albokhadaim I, Kandeel M, et al (2023) From imbalance to impairment: the central role of reactive oxygen species in oxidative stress-induced disorders and therapeutic exploration. Front Pharmacol 14: 1269581.
19. Madreiter-Sokolowski CT, Hiden U, Krstic J, Panzitt K, Wagner M, et al (2024) Targeting organ-specific mitochondrial dysfunction to improve biological aging. Pharmacol Ther 262: 108710.
20. Santos AL, Sinha S and Lindner AB (2018) The Good, the Bad, and the Ugly of ROS: New Insights on Aging and Aging-Related Diseases from Eukaryotic and Prokaryotic Model Organisms. Oxid Med Cell Longev 2018: 1941285.
21. Lima MC de AM, Zazula MF, Martins LF, Martins LF, Carvalhal SR, et al (2024) How soon do metabolic alterations and oxidative distress precede the reduction of muscle mass and strength in Wistar rats in aging process? Biogerontology 25(3): 491-506.
22. Gambini J and Stromsnes K (2022) Oxidative Stress and Inflammation: From Mechanisms to Therapeutic Approaches. Biomedicines 10(4): 753.
23. Xu X, Pang Y and Fan X (2025) Mitochondria in oxidative stress, inflammation and aging: from mechanisms to therapeutic advances. Signal Transduct Target Ther 10(1): 190.
24. Yang HM (2025) Mitochondrial Dysfunction in Cardiovascular Diseases. Int J Mol Sci 26(5): 1917.
25. Martini H and Passos JF (2023) Cellular senescence: all roads lead to mitochondria. FEBS J 290(5): 1186-1202.
26. Sizek H, Deritei D, Fleig K, Harris M, Regan PL, et al (2024) Unlocking mitochondrial dysfunction-associated senescence (MiDAS) with NAD+ - A Boolean model of mitochondrial dynamics and cell cycle control. Transl Oncol 49: 102084.
27. Wan W, Zhang L, Lin Y, Rao X, Wang X, et al (2023) Mitochondria-derived peptide MOTS-c: effects and mechanisms related to stress, metabolism and aging. J Transl Med 21(1): 36.
28. Xiao F, Zhou H and Lin H (2025) Decoding small peptides: Regulators of plant growth and stress resilience. J Integr Plant Biol 67(3): 596-631.
29. Abu Shelbayeh O, Arroum T, Morris S and Busch KB (2023) PGC-1α Is a Master Regulator of Mitochondrial Lifecycle and ROS Stress Response. Antioxid Basel Switz 12(5): 1075.
30. Lakey JR, Wells A, Good A, Damyar K, Tucker TR, et al (2022) Protective Effects of Stem Cell-Derived Peptides in Preventing Autoimmune Diabetes in the Non-Diabetic Mouse Model. Am J Biomed Sci Res 16(5).
31. Chan MKS, Wong MBF, Casazza K, Klokol D, Nishkumai O, et al (2025) Peptide-Based Precision Therapeutics for Cardiac Disease: Targeting Mitochondrial Dysfunction, Fibrosis, and Inflammation. Am J Biomed Sci Res 27(3).
32. Chan MKS, Wong MBF, Casazza K and Lakey JR (2025) Emerging Peptide Therapies for Kidney Disease: Focus on Nano-Organo and Mitochondria-Targeted Strategies. Am J Biomed Sci Res 27(3).
33. Cheng X, Xie Q and Sun Y (2023) Advances in nanomaterial-based targeted drug delivery systems. Front Bioeng Biotechnol 11: 1177151.
34. Chan MKS, Wong MBF, Nalapko Y, Casazza K, Klokol D, et al (2025) Short-Peptides May be the Key to Long Life. Am J Biomed Sci Res 26(2).
35. Philippe GJB, Craik DJ and Henriques ST (2021) Converting peptides into drugs targeting intracellular protein-protein interactions. Drug Discov Today 26(6): 1521-1531.
36. Zhu C, Mu J and Liang L (2024) Nanocarriers for intracellular delivery of proteins in biomedical applications: strategies and recent advances. J Nanobiotechnology 22(1): 688.
37. Jomova K, Alomar SY, Alwasel SH, Nepovimova E, Kuca K, et al (2024) Several lines of antioxidant defense against oxidative stress: antioxidant enzymes, nanomaterials with multiple enzyme-mimicking activities, and low-molecular-weight antioxidants. Arch Toxicol 98(5): 1323-1367.
38. Park JM, Lee DH and Kim DH (2023) Redefining the role of AMPK in autophagy and the energy stress response. Nat Commun 14(1): 2994.
39. Dominy JE and Puigserver P (2013) Mitochondrial biogenesis through activation of nuclear signaling proteins. Cold Spring Harb Perspect Biol 5(7): a015008.
40. Wang L, Wang N, Zhang W, Cheng X, Yan Z, et al (2022) Therapeutic peptides: current applications and future directions. Signal Transduct Target Ther 7(1): 48.
41. Clemente-Suárez VJ, Redondo-Flórez L, Beltrán-Velasco AI, Rodríguez AM, Guardado IM, et al (2023) The Role of Adipokines in Health and Disease. Biomedicines 11(5): 1290.
42. Oduwole OO, Huhtaniemi IT and Misrahi M (2021) The Roles of Luteinizing Hormone, Follicle-Stimulating Hormone and Testosterone in Spermatogenesis and Folliculogenesis Revisited. Int J Mol Sci 22(23): 12735.
43. Xiao W, Jiang W, Chen Z, Huang Y, Mao J, et al (2025) Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines. Signal Transduct Target Ther 10(1): 74.
44. Hekım MG, Ozcan S, Yur M, Yıldırım N and Ozcan M (2023) Exploring the potential of humanin as a biomarker for early breast cancer detection: a study of serum levels and diagnostic performance. Biomark Biochem Indic Expo Response Susceptibility Chem 28(6): 555-561.
45. Christensen IB, Abrahamsen ML, Ribas L, Buch-Larsen K, Marina D, et al (2023) Peripheral blood mononuclear cells exhibit increased mitochondrial respiration after adjuvant chemo- and radiotherapy for early breast cancer. Cancer Med 12(16): 16985-16996.
46. Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, et al (2018) Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol Off J Am Soc Clin Oncol 36(17): 1714-1768.
47. Glaab E, Rauschenberger A, Banzi R, Gerardi C, Garcia P, et al (2021) Biomarker discovery studies for patient stratification using machine learning analysis of omics data: a scoping review. BMJ Open 11(12): e053674.